We don't think so—with all of the data being publicly available, different opinions can now be
discussed openly. Concerning the transparency of clinical trial information from regulatory …

Regulatory agencies such as Health Can ada and the US Food and Drug Adminis tration
(FDA) have to date treated sub missions of clinical trial data as confidential business …

The Blueprint for Transparency at the FDA recommends that the FDA proactively release
more clinical trial data. We show that the FDA possesses the legal authority to act on this …

details about commercially sensitive data, the real problem for granting unfettered access to
clinical trial data is patient confidentiality. EMA and other regulatory bodies were still …

FOLLOWING CONSIDERABLE PRESSURE over policies related to the accessibility of
unpublished clinical trial data in its database and conflicts of interest for its officials …

Transparency and the European Medicines Agency — Sharing of Clinical Trial Data | NEJM
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn …

Purpose Quality of care is strongly influenced by evidence-based medicine, a large part of
which is based on results obtained from clinical trials. If trials are conducted in secret, patient …

Objective To evaluate the accuracy of a 2015 cross-sectional analysis published in the BMJ
Open which reported that pharmaceutical industry compliance with clinical trial registration …

The loss of public trust in the clinical research community, particularly in the pharmaceutical
industry, came after a series of allegations focusing on selective reporting of clinical trial …

Abstract The European Medicines Agency has opened a window to access clinical trial data.
This is an important step forward which deserves attention, support, and advice from all the …